Concepedia

Thomas Holbro

TH

12

Publications

1.8K

Citations

12

H-Index

2001

Active since

Affiliations

Novartis (Switzerland)(Current)

Friedrich Miescher Institute

San Francisco VA Medical Center

University of Brescia

University of California, San Francisco

Thomas Holbro is an author at Novartis (Switzerland) specializing in medicine, breast cancer, and cell biology.

Top concepts

MedicineCell BiologyBreast CancerTumor BiologyCell SignalingCell CycleCancer BiologySystems BiologyRadiation OncologySignal Transduction

Publications per year

2001–2021

12

Publications

12

The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation

Thomas Holbro, Roger R. Beerli, Francisca Maurer et al. · Proceedings of the National Academy of Sciences · 2003 · 954 citations · Full text

Signal Transduction, Signaling Pathway, Active Erbb2 +13

Effects of Serelaxin in Patients with Acute Heart Failure

Marco Metra, John R. Teerlink, Gad Cotter et al. · New England Journal of Medicine · 2019 · 253 citations · Full text

Blocking of FGFR signaling inhibits breast cancer cell proliferation through downregulation of D-type cyclins

Magdalena Koziczak, Thomas Holbro, Nancy E. Hynes · Oncogene · 2004 · 160 citations

Radiation Oncology, Breast Oncology, Breast Cancer +6

Wnt1 and Wnt5a induce cyclin D1 expression through ErbB1 transactivation in HC11 mammary epithelial cells

Gianluca Civenni, Thomas Holbro, Nancy E. Hynes · EMBO Reports · 2003 · 132 citations · Full text

Erbb1 Transactivation, Signaling Pathway, Cell Regulation +8

Distinct roles for phosphoinositide 3-kinase, mitogen-activated protein kinase and p38 MAPK in mediating cell cycle progression of breast cancer cells

Richard M. Neve, Thomas Holbro, Nancy E. Hynes · Oncogene · 2002 · 114 citations

Phosphoinositide 3-Kinase, Signal Transduction, Signaling Pathway +12

Rows per page

1–5 of 12